Table 2.

Risk factors for recurrence in all patients.

	Odds ratios	95%CI	p-value
Age (≥65 years)	1.322	0.714–2.446	0.374
Male	1.378	0.717–2.649	0.336
APR, TP	3.073	1.479–6.384	0.003
LAP	0.560	0.280–1.120	0.101
Obstraction	3.078	0.932–10.165	0.065
T4	4.859	0.902–26.174	0.066
lymphatic invasion	2.080	1.055–4.101	0.034
vascular invasion	2.702	1.300–5.615	0.008
Poorly tumor differentiation	1.212	0.521–2.821	0.656
number of lymph node resection (<12)	2.081	1.076–4.025	0.029
CEA (>5 ng/mL)	0.991	0.416–2.357	0.983
Neoadjuvant therapy
CRT/none	2.168	0.911–5.160	0.080
CRT/CT	0.451	0.049–4.108	0.480
CRT/RT	1.248	0.098–15.867	0.864
CT/none	4.811	0.536–43.219	0.161
CT/RT	2.770	0.104–73.469	0.542
RT/none	1.737	0.148–20.338	0.660
Adjuvant therapy
Ox/Non-Ox	1.932	0.318–11.726	0.474
Ox/nonCT	2.011	0.366–11.040	0.421
Non-Ox/nonCT	1.041	0.495–2.190	0.916
Odds ratios for recurrence were calculated using regression analysis. Values in parentheses are 95 % confidence intervals. APR, abdominoperineal resection; TP, total pelvic exenteration; LAP, laparoscopic surgery; CEA, carcinoembryonic antigen; CRT, chemoradiotyherapy; CT, chemotherapy; RT, radiotherapy; none, no neoadjuvant therapy; Ox, oxaliplatin-based chemothetapy; Non-Ox, nonoxaliplatin-based chemotherapy; nonCT, no chemotherapy.